Background: NCRAD is a National Institute on Aging (NIA) cooperative grant, awarded to Indiana University since 1990, whose purpose is to serve as a biorepository for AD/ADRD researchers. With 74 participating across 150 unique institutions, NCRAD links specimens to clinical research data. NCRAD maintains over 2 million aliquots from more than 126,000 research participants spanning a wide range of AD/ADRD related phenotypes as well as healthy controls.
Method: To ensure standardization and uniformity, NCRAD develops a manual of procedures specific to each study protocol that includes detailed pictures, schematics, and flow charts for each sample type collected. NCRAD conducts web-based training for site staff and provides supplemental training videos to ensure Researchers receiving samples from NCRAD agree to share the data generated from the samples. Since its inception, NCRAD has distributed over 410,000 samples to more than 200 researchers. NCRAD biospecimens and data have been reported in more than 850 publications.
Result: NCRAD's mission is to maintain uniformity in collection and processing of samples sites involved in each study. Centralized biobanking and broad sharing of biospecimens has accelerated research discovery.
Conclusion: Using standardized biospecimen collection, processing, shipping, storage, and distribution procedures established at NCRAD, in conjunction with attention to detail, strict compliance with regulations, and oversight from the NIA, has resulted in a biorepository with highest quality samples available to researchers investigating the etiology, early detection and therapeutic development for AD/ADRD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.087810 | DOI Listing |
Alzheimers Dement
December 2024
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Background: NCRAD is a National Institute on Aging (NIA) cooperative grant, awarded to Indiana University since 1990, whose purpose is to serve as a biorepository for AD/ADRD researchers. With 74 participating across 150 unique institutions, NCRAD links specimens to clinical research data. NCRAD maintains over 2 million aliquots from more than 126,000 research participants spanning a wide range of AD/ADRD related phenotypes as well as healthy controls.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD), Indianapolis, IN, USA.
Background: The National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) is continuing to develop a bank of induced pluripotent stem cells (iPSCs) that are available by request to the Alzheimer's disease (AD) research community.
Methods: As part of the pipeline for quality control of received cell lines, DNA was extracted for all lines and was submitted for whole genome sequencing (WGS). Paired-end WGS data was generated using the Illumina NovaSeq 6000 and processed following GATK best practices using the Sentieon pipeline.
Alzheimers Dement
December 2024
1501 NW 10th Avenue, Miami, FL, USA.
Background: The ADSP is a National Institute on Aging (NIA) initiative focused on identifying genetic risk and protective variants for Alzheimer Disease (AD). Initial phases (Discovery and Discovery Extension) were predominantly non-Hispanic Whites of European Ancestry (NHW-EA). The ADSP expanded the population diversity in the Follow Up Study (ADSP-FUS), and the current phase, ADSP-FUS 2.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Jackson Laboratory, Bar Harbor, ME, USA.
Background: There is strong evidence that underlying genetics of an individual can significantly modify response to development of amyloid and tau pathology with age. Genome-wide association studies indicate that variation in more than 25 genetic loci relevant to microglial biology are predicted to increase susceptibility to Alzheimer's disease (AD). This work aims to understand how genetic context can impact microglia function, how these differences relate to AD pathology, and ultimately, cognitive decline.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!